Medicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma Treatment

An update from Medicus Pharma Ltd ( (MDCX) ) is now available.

Medicus Pharma Ltd. announced an expansion of its phase 2 clinical study for treating nodular basal cell carcinoma (BCC), increasing the number of patients from 60 to 90 and adding trial sites in Europe. The study, which has shown promising interim results with over 60% of subjects achieving complete clinical clearance, aims to secure global validation for its novel treatment. The investigational product, D-MNA, has been well tolerated with no serious adverse events reported, and the company plans to seek a meeting with the FDA by the end of Q2 2025.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.

Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets. Its subsidiary, SkinJect Inc., specializes in developing non-invasive treatments for basal cell skin cancer using patented dissolvable microneedle patches to deliver chemotherapeutic agents.

YTD Price Performance: 64.61%

Average Trading Volume: 56,411

Technical Sentiment Signal: Strong Sell

Current Market Cap: $49.01M

For an in-depth examination of MDCX stock, go to TipRanks’ Stock Analysis page.